ALEC
Price
$2.00
Change
+$0.17 (+9.29%)
Updated
Oct 27, 12:41 PM (EDT)
Capitalization
204.33M
9 days until earnings call
Intraday BUY SELL Signals
VYGR
Price
$1.78
Change
+$0.03 (+1.71%)
Updated
Oct 27, 01:30 PM (EDT)
Capitalization
107.83M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALEC vs VYGR

ALEC vs VYGR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALEC vs. VYGR commentary
Oct 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a Buy and VYGR is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALEC with price predictions
Oct 26, 2026

ALEC sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ALEC moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +7.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 88 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for ALEC turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

ALEC moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALEC crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ALEC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.495) is normal, around the industry mean (3.037). P/E Ratio (-1.679) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VYGR with price predictions
Oct 26, 2026

VYGR's RSI Oscillator stays in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +15.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 229 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for VYGR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.698) is normal, around the industry mean (3.037). P/E Ratio (-0.967) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALEC vs VYGR: Fundamental Ratings
ALEC
VYGR
OUTLOOK RATING
1..100
4671
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5291
P/E GROWTH RATING
1..100
7512
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALEC's Valuation (8) in the Biotechnology industry is somewhat better than the same rating for VYGR (47). This means that ALEC’s stock grew somewhat faster than VYGR’s over the last 12 months.

ALEC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VYGR (100). This means that ALEC’s stock grew similarly to VYGR’s over the last 12 months.

VYGR's SMR Rating (98) in the Biotechnology industry is in the same range as ALEC (100). This means that VYGR’s stock grew similarly to ALEC’s over the last 12 months.

ALEC's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for VYGR (91). This means that ALEC’s stock grew somewhat faster than VYGR’s over the last 12 months.

VYGR's P/E Growth Rating (12) in the Biotechnology industry is somewhat better than the same rating for ALEC (75). This means that VYGR’s stock grew somewhat faster than ALEC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALECVYGR
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
72%
COMPARISON
Comparison
Oct 27, 2026
Stock price -- (ALEC: $1.83 vs. VYGR: $1.75)
Brand notoriety: ALEC and VYGR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALEC: 107% vs. VYGR: 251%
Market capitalization -- ALEC: $204.33M vs. VYGR: $107.83M
ALEC [@Biotechnology] is valued at $204.33M. VYGR’s [@Biotechnology] market capitalization is $107.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $131.16B. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALEC’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).

  • ALEC’s FA Score: 1 green, 4 red.
  • VYGR’s FA Score: 1 green, 4 red.
According to our system of comparison, VYGR is a better buy in the long-term than ALEC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALEC’s TA Score shows that 3 TA indicator(s) are bullish while VYGR’s TA Score has 4 bullish TA indicator(s).

  • ALEC’s TA Score: 3 bullish, 6 bearish.
  • VYGR’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, VYGR is a better buy in the short-term than ALEC.

Price Growth

ALEC (@Biotechnology) experienced а -6.15% price change this week, while VYGR (@Biotechnology) price change was -14.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.65%. For the same industry, the average monthly price growth was -11.32%, and the average quarterly price growth was -14.09%.

Reported Earning Dates

ALEC is expected to report earnings on Nov 05, 2026.

VYGR is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ALEC
Daily Signal:
Gain/Loss:
VYGR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMDY42.550.95
+2.28%
YieldMax AMD Option Income Strategy ETF
RZG61.890.24
+0.40%
Invesco S&P Smallcap 600 Pure Growth ETF (RZG)
RWJ58.020.10
+0.17%
Invesco S&P SmallCap 600 Revenue ETF (RWJ)
PAWZ51.91-0.07
-0.14%
ProShares Pet Care ETF (PAWZ)
ORO19.60-0.08
-0.40%
Arrow Valtoro ETF (ORO)